{
    "data": [
        {
            "id": "69a1889424c37e0001bbe5e9",
            "title": "12 Health Care Stocks Moving In Friday&#39;s Pre-Market Session",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><h3 class=\"block core-block\">Gainers</h3><!--/$--><!--$--><ul class=\"block core-block\">\n<li><strong>Ensysce Biosciences</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ENSC\" target=\"_blank\">ENSC</a>) shares rose 40.4% to $0.55 during Friday's pre-market session. The market value of their outstanding shares is at $1.3 million. </li>\n<li><strong>Cardio Diagnostics Hldgs</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CDIO\" target=\"_blank\">CDIO</a>) stock rose 23.18% to $6.43. The market value of their outstanding shares is at $9.5 million. </li>\n<li><strong>Neurogene</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NGNE\" target=\"_blank\">NGNE</a>) shares rose 20.93% to $23.8. The company's market cap stands at $304.8 million. </li>\n<li><strong>Caris Life Sciences</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CAI\" target=\"_blank\">CAI</a>) stock increased by 14.81% to $22.09. The market value of their outstanding shares is at $5.4 billion. As per the press release, Q4 earnings came out yesterday. </li>\n<li><strong>BioAtla</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/BCAB\" target=\"_blank\">BCAB</a>) shares moved upwards by 10.78% to $0.26. The market value of their outstanding shares is at $17.6 million. </li>\n<li><strong>Candel Therapeutics</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CADL\" target=\"_blank\">CADL</a>) stock increased by 8.73% to $5.6. The company's market cap stands at $282.7 million. </li>\n</ul><!--/$--><!--$--><h3 class=\"block core-block\">Losers</h3><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/movers_1.jpg",
            "link": "https://www.benzinga.com/insights/movers/26/02/50923004/12-health-care-stocks-moving-in-fridays-pre-market-session",
            "pub_date": "2026-02-27 20:05:45",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1889a24c37e0001bbe5f2",
            "title": "12 Consumer Discretionary Stocks Moving In Friday&#39;s Pre-Market Session",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><h3 class=\"block core-block\">Gainers</h3><!--/$--><!--$--><ul class=\"block core-block\">\n<li><strong>707 Cayman Holdings</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/JEM\" target=\"_blank\">JEM</a>) stock rose 22.2% to $0.11 during Friday's pre-market session. The market value of their outstanding shares is at $1.7 million. </li>\n<li><strong>RealReal</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/REAL\" target=\"_blank\">REAL</a>) shares rose 10.57% to $13.7. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out yesterday. </li>\n<li><strong>Kandal M Venture</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/FMFC\" target=\"_blank\">FMFC</a>) stock rose 8.13% to $0.47. The company's market cap stands at $7.9 million. </li>\n<li><strong>FIGS</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/FIGS\" target=\"_blank\">FIGS</a>) shares increased by 6.65% to $13.3. The company's market cap stands at $2.0 billion. The company's, Q4 earnings came out yesterday. </li>\n<li><strong>Robo.ai</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/AIIO\" target=\"_blank\">AIIO</a>) shares rose 5.91% to $0.13. The company's market cap stands at $42.2 million. </li>\n<li><strong>Mixed Martial Arts Group</strong> (AMEX:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/MMA\" target=\"_blank\">MMA</a>) stock moved upwards by 5.01% to $0.58. The market value of their outstanding shares is at $14.6 million. </li>\n</ul><!--/$--><!--$--><h3 class=\"block core-block\">Losers</h3><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/movers_1.jpg",
            "link": "https://www.benzinga.com/insights/movers/26/02/50923013/12-consumer-discretionary-stocks-moving-in-fridays-pre-market-session",
            "pub_date": "2026-02-27 20:05:49",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1877224c37e0001bbe49b",
            "title": "Demystifying Solventum: Insights From 5 Analyst Reviews",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">In the latest quarter, 5 analysts provided ratings for Solventum (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SOLV\" target=\"_blank\">SOLV</a>), showcasing a mix of bullish and bearish perspectives.</p><!--/$--><!--$--><p class=\"block core-block\">The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $100.4, a high estimate of $105.00, and a low estimate of $97.00. This upward trend is apparent, with the current average reflecting a 10.33% increase from the previous average price target of $91.00.</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Analyzing Analyst Ratings: A Detailed Breakdown</h2><!--/$--><!--$--><p class=\"block core-block\">The analysis of recent analyst actions sheds light on the perception of Solventum by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Key Insights:</h3><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">To gain a panoramic view of Solventum's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/quote/SOLV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage\" target=\"_blank\"><strong>Stay up to date on Solventum analyst ratings.</strong></a></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Unveiling the Story Behind Solventum</h2><!--/$--><!--$?--><template id=\"B:5\"></template><div></div><!--/$--><!--$--><h3 class=\"block core-block\">Solventum: A Financial Overview</h3><!--/$--><!--$--><p class=\"block core-block\"><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Revenue Growth:</strong> Solventum's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>0.67%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Net Margin:</strong> Solventum's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>60.4%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Equity (ROE):</strong> Solventum's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>29.34%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Assets (ROA):</strong> Solventum's ROA excels beyond industry benchmarks, reaching <strong>8.72%</strong>. This signifies efficient management of assets and strong financial health.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Debt Management:</strong> Solventum's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.03</strong>.</p><!--/$--><!--$--><h2 class=\"block core-block\">The Significance of Analyst Ratings Explained</h2><!--/$--><!--$--><p class=\"block core-block\">Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p><!--/$--><!--$--><p class=\"block core-block\">In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_5.jpg",
            "link": "https://www.benzinga.com/insights/analyst-ratings/26/02/50922669/demystifying-solventum-insights-from-5-analyst-reviews",
            "pub_date": "2026-02-27 20:00:55",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1877a24c37e0001bbe4a1",
            "title": "The Analyst Verdict: Dollar Tree In The Eyes Of 18 Experts",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">Throughout the last three months, 18 analysts have evaluated Dollar Tree (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/DLTR\" target=\"_blank\">DLTR</a>), offering a diverse set of opinions from bullish to bearish.</p><!--/$--><!--$--><p class=\"block core-block\">The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $129.17, a high estimate of $160.00, and a low estimate of $85.00. This upward trend is apparent, with the current average reflecting a 6.75% increase from the previous average price target of $121.00.</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Deciphering Analyst Ratings: An In-Depth Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">A comprehensive examination of how financial experts perceive Dollar Tree is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Key Insights:</h3><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">For valuable insights into Dollar Tree's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/quote/DLTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage\" target=\"_blank\"><strong>Stay up to date on Dollar Tree analyst ratings.</strong></a></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Get to Know Dollar Tree Better</h2><!--/$--><!--$?--><template id=\"B:5\"></template><div></div><!--/$--><!--$--><h3 class=\"block core-block\">Dollar Tree: A Financial Overview</h3><!--/$--><!--$--><p class=\"block core-block\"><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Revenue Growth:</strong> Dollar Tree displayed positive results in 3M. As of 31 October, 2025, the company achieved a solid revenue growth rate of approximately <strong>9.44%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company excelled with a growth rate higher than the average among peers.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Net Margin:</strong> Dollar Tree's net margin is impressive, surpassing industry averages. With a net margin of <strong>5.15%,</strong> the company demonstrates strong profitability and effective cost management.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>6.92%,</strong> the company showcases effective utilization of equity capital.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Assets (ROA):</strong> Dollar Tree's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.81%,</strong> the company showcases efficient use of assets and strong financial health.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.21</strong>, Dollar Tree faces challenges in effectively managing its debt levels, indicating potential financial strain.</p><!--/$--><!--$--><h2 class=\"block core-block\">The Significance of Analyst Ratings Explained</h2><!--/$--><!--$--><p class=\"block core-block\">Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p><!--/$--><!--$--><p class=\"block core-block\">In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_2.jpg",
            "link": "https://www.benzinga.com/insights/analyst-ratings/26/02/50922675/the-analyst-verdict-dollar-tree-in-the-eyes-of-18-experts",
            "pub_date": "2026-02-27 20:01:01",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1835124c37e0001bbe356",
            "title": "Binance Arbitration Push Denied By Judge In Crypto Loss Dispute Involving Changpeng Zhao",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">A federal judge on Thursday rejected a request by cryptocurrency exchange <strong>Binance</strong> <a class=\"ticker-link\" data-exchange=\"CRYPTO\" data-ticker=\"BNB\" href=\"https://www.benzinga.com/quote/BNB-USD\" rel=\"noopener\" target=\"_blank\">(CRYPTO: </a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/bnb/usd\" target=\"_blank\">BNB</a>)<!-- --> for arbitration in a case involving customer claims over losses from unregistered tokens.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Customers Can Pursue Claims, Rules Judge</h2><!--/$--><!--$--><p class=\"block core-block\">U.S. District Judge <strong>Andrew Carter </strong>of the Southern District of New York ruled that Binance failed to adequately inform its customers about changes to its terms of usage, reported Reuters. These changes included an arbitration requirement and a class-action waiver. </p><!--/$--><!--$--><p class=\"block core-block\">Carter deemed the alleged class-action waiver in Binance’s 2019 terms of use “ambiguous and unenforceable.”</p><!--/$--><!--$--><p class=\"block core-block\">A Binance spokesperson told Benzinga that the company would “vigorously defend the limited claims that remain in this meritless case.” </p><!--/$--><!--$--><p class=\"block core-block\">Notably, the plaintiffs agreed to drop all claims that arose after Feb. 20, 2019.</p><!--/$--><!--$--><p class=\"block core-block\">The lawsuit, originally filed in 2021 and revived by appeals in 2024 after a 2022 dismissal, accuses Binance and founder <strong>Changpeng Zhao</strong> of violating securities laws by selling high-risk tokens without adequate warnings.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Price Action</strong>: At the time of writing, BNB was exchanging hands at $624.71, down 0.78% in the last 24 hours, according to data from Benzinga Pro.</p><!--/$--><!--$--><p class=\"block core-block\"><strong><em>Disclaimer:</em></strong><em> This content was partially produced with the help of <a href=\"https://www.benzinga.com/author/benzinga-neuro\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.</em></p><!--/$--><!--$--><p class=\"block core-block\"><em>Image via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-middle-50922355\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Dhaka--Bangladesh-22-September-2025bitco.jpeg",
            "link": "https://www.benzinga.com/crypto/26/02/50922355/binance-arbitration-push-denied-by-judge-in-crypto-loss-dispute-involving-changpeng-zhao",
            "pub_date": "2026-02-27 19:43:17",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}